Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 17Surveys and Questionnaires 12Specimen Handling 11Docetaxel 11Nivolumab 9Interviews as Topic 9Standard of Care 8Gemcitabine 8Early Intervention, Educational 8olaparib 7enzalutamide 7Magnetic Resonance Spectroscopy 7Psychiatric Rehabilitation 6Paclitaxel 6durvalumab 5Trastuzumab 5Radiotherapy 5Ipilimumab 5Carboplatin 5Bevacizumab 5pertuzumab 4palbociclib 4cabozantinib 4atezolizumab 4abiraterone 4Therapeutics 4Taxes 4Oxaliplatin 4Methods 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × mocetinostat × Gastrointestinal × Clear all
NCT00511576 2015-01-08

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Mirati Therapeutics Inc.

Phase 1 Terminated
54 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡